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1. Introduction
   Hepatocellular carcinoma (HCC) is among the most lethal and 
common malignancies in the human population, with approximately 
550 000 new cases and almost as many deaths per year[1,2]. For 
instance, a highly rate of HCC is observed in Egypt, where there 
is high prevalence of hepatitis B and C viral infections[3]. It is 
noteworthy that it is too hardly to eliminate hepatitis viruses 
infection, therefore chemoprevention could be the more suitable 
challenge with the HCC, especially in carriers of hepatitis B and 
C viruses[4]. Locally available plants could provide accessible and 
economically feasible sources for herbal HCC preventives. Aloe 
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Objective: To investigate the in vitro anticancer effect of Aloe vera (A. vera) and Calligonum 
comosum (C. comosum) extracts against hepatocellular carcinoma (HepG2) cells.  
Methods: HepG2 cells were tested against different doses of A. vera and C. comosum. 
Viability of the cells was assessed by MTT assay. Evaluation of apoptosis and DNA damage 
in HepG2 cells were performed using annexin V apoptosis detection kit. The expression of 
p53 and anti-apoptotic (Bcl-2) were tested by real time-PCR and flow cytometer analyser. 
Hematoxylin and eosin stained sections from untreated and treated HepG2 cells were observed 
using light microscopy.
Results: The IC50 values of A. vera and C. comosum extracts were (10.45 μ 0.31) and (9.60 μ 
0.01) øg/mL respectively. The extracts separately increased cytotoxicity against HepG2 cells 
in a time and dose dependent manners. Also, it apparently induced apoptosis through increase 
P53 and decrease Bcl-2 genes expressions.
Conclusions: The results indicated that the extracts could have anti-hepatocarcinogenic effect, 
at least in part, through modulation of apoptosis.
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Comments
Up-regulation of expression of p53 and 
down-regulation of Bcl2 in a time and dose 
dependent manner were evident in the 
human hepatocellular carcinoma cell line 
which is a major pathway for regulation 
of programmed cell death. Both extracts 
could have cytotoxic and genotoxic activity. 
C. comosum showed a higher level in 
inducing morphological changes associated 
apoptosis, DNA damage, gene and protein 
expressions. In conclusion, the present 
study demonstrated that the herbal extracts 
of A. vera and C. comosum could induce 
cytotoxic and genotoxic activites on human 
hepatocellular carcinoma (HepG2) cells 
through induction of apoptotic pathway. 
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vera (A. vera) and Calligonum comosum (C. comosum) „arta‰ 
are Egyptian plants that are used as source of medicine in rural 
areas. Apoptosis is a genetically controlled process of selective 
cell deletion involved in normal cell development and turnover[5]. 
Apoptosis is controlled by the expression of several regulatory 
genes, including c-myc, p53 and apo-1/fas[6]. P53 is a tumor 
suppressor gene acting as a guardian of the genome through 
conserving its stability and initiating apoptosis of DNA damaged 
cells. Also, it is the most commonly mutated gene in human 
cancers[7,8]. However, one of the most important advances in our 
understanding of apoptotic cell death has come from studies of the 
oncogenic Bcl-2 family. Bcl-2 promotes cell survival by blocking 
apoptosis induced by a range of stimuli including growth factor 
withdrawal[9]. Therefore, the aim of the present study was to 
evaluate the anti-tumor effect of different doses of A. vera and C. 
comosum extracts on HCC through assessment in vitro cytotoxicity 
induced apoptosis in HepG2 cell line.
2. Materials and methods
2.1. Drugs and reagents
 
   Lyophilized A. vera extract (Coral Vegetable, Miyakojima, 
Japan) and methanolic extract of C. comosum were dissolved to a 
concentration of 0.1 mol/L in dimethyl sulfoxide (DMSO) as a stock 
solution and stored at -20 ÀC. The working concentrations used in 
this study were from 10 ømol/L to 2 000 ømol/L and were freshly 
diluted with medium before each experiment with a final DMSO 
concentration of less than 0.1%. Then the extracts were diluted with 
DulbeccoÊs modified EagleÊs medium to desired concentrations of A. 
vera (2.50, 7.50 and 10.45 øg/mL) and C. comosum (2.5, 7.5 and 9.6 
øg/mL) for 48 h, and control with 1% DMSO. Cells were washed with 
phosphate buffer saline (PBS) and trypsinized for collecting different 
aliquots for studying DNA damage, apoptosis markers and cell cycle 
by flow cytometry.
2.2. Cell culture
   Human hepatocellular carcinoma (HepG2) cell lines were 
maintained at laboratories of Medical Experimental Research 
Center, Faculty of Medicine, Mansoura University. The cell culture 
medium was DulbeccoÊs modified EagleÊs medium supplemented 
with 10% fetal bovine serum, 100 IU/mL penicillin and 100 øg/mL 
streptomycin. The cells were cultured at 37 ÀC under a humidified 
atmosphere containing 5% CO2. Cells were placed in a 75 cm
2 tissue 
culture flask.
2.3. Evaluation of HepG2 cell viability by MTT assay
   Effect on overall cell activity was determined by performing the 
MTT assay based on the method of Oka et al.,[10] using MTT assay 
kit.  
IC50 (%) = [100 ė (Absorbance of control groupî- Absorbance of 
treated group] / Absorbance of control group.
2.4. Assay for apoptosis and DNA damage 
   The concentrations of A. vera used were 2.50, 7.50, and 10.45 
øg/mL. The concentrations of C. comosum used were 2.5, 7.5, 
and 9.6 øg/mL, and triplicate cell cultures were exposed to each 
concentration. Treated and control cell cultures were harvested 
and stained by hematoxylin and eosin (H&E)[11]. Apoptosis and 
DNA damage were detected by using an Annexin V-FITC apoptosis 
detection kit (Cat. no. APOAF, Sigma, USA). Treated and control cells 
were washed twice with PBS and resuspended in 1-fold binding buffer 
at a concentration of 1ė106 cells/mL. Five microliter of Annexin V 
FITC Conjugate and 10 øL of propidium iodide solution were added 
to 500 øL of each cell suspension, incubated at room temperature for 
10 min, and then analyzed by flow cytometry  instrument (FACStar 
caliber, Becton Dickinson, USA) using 488 nm excitation and a 515 
nm band pass filter for FITC detection and a filter over 600 nm for 
PI detection. The percentage of each phase was calculated with the 
software Cell-Quest[12].  
2.5. Detection of Bcl2 and P53 genes expression (real time –PCR)
                                                                                                                                            
 
   Isolation of total RNA and real time-PCR analysis of p53 and Bcl2 
genes were applied in HepG2 cells as mentioned in Shak et al.[13]. 
HepG2 cells were cultured for 24 h then incubated for 48 h with 
fresh medium containing different concentrations of the extracts (test 
cells) or 1% DMSO (control cells). The concentrations of A. vera used 
were 2.50, 7.50 and 10.45 øg/mL. The concentrations of C. comosum 
used were 2.5, 7.5 and 9.6 øg/mL, and triplicate cell cultures were 
exposed to each concentration. Treated and control cell cultures 
were harvested and used for total RNA extraction. Total RNA was 
isolated from the HepG2 cells using RNA extraction kit (GF-1 total 
RNA extraction, Vivantis, Malasyia) according to the manufacturerÊs 
specifications. The quantity and quality of the extracted RNA were 
determined by measuring the absorbance at 230, 260 and 280 nm of 
the spectrophotometer (Nano drop 2000, Thermo Scientific, USA) and 
2 characteristic bands of RNA were appeared by gel electrophoresis. 
One microgram of total RNA was synthesized cDNA by using Thermo 
Scientific kit (Maxima First Strand cDNA kit, Thermo Scientific, 
USA). Primers were designed online in NCBI site and real-time PCR 
was performed by using Syber Green dye (QuantiTect Sybr Green 
PCR kit, Qiagen, USA) according to manufacturerÊs instructions. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was preserved 
as a reference gene. Table 1 shows the primer sequences which were 
used in the amplification. 
Table 1 
Primer sequences for real time-PCR.
Name of gene Primer forward Primer reverse
p53 TGAGGTGCGTGTTTGTGCCTGT TCGGAACATCTCGAAGCGCTCA
Bcl-2 ATCGCCCTGTGGATGACTGAG CAGCCAGGAGAAATCAAACAGAGG
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC
2.6. Determination of p53 and Bcl2 proteins by flow cytometry
2.6.1. Detection of p53
   The tested and control cells were fixed with 4% paraformaldehyde 
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(10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. 
The cells were incubated in 1-fold PBS/ 10% normal goat serum/ 
0.3 mol/L glycine to block non-specific protein-protein interactions 
followed by the Anti-p53 antibody [DO-1] (ab1101, 1:50 dilution, 
abcam, San Francisco, USA) for 30 min at 22 ÀC and then analyzed 
using FACStar caliber (Becton Dickinson).
2.6.2. Detection of Bcl2 
   The tested and control cells were fixed with 80% methanol for 5 
min. Then permeabilized with 0.1% PBS-Tween for 20 min. The 
cells were then incubated in 1-fold PBS/ 10% normal goat serum/ 
0.3 mol/L glycine to block non-specific protein-protein interactions 
followed by Anti-Bcl2A1 antibody ((ab33862) (1/100 dilution, 
abcam, San Francisco, USA) for 30 min at 22 ÀC.
2.7. Statistical analysis
   The parameters in this study were subjected to statistical analysis 
using Microsoft excel spread sheet. For analysis of the data SPSS 
version 15 and EPIINFO 2006 softwareÊs were used.
3. Results
3.1. Effect of A. vera and C. comosum on cell viability
   MTT reduction assay was performed to study mitochondrial/
non mitochondrial dehydrogenase activity as a cytotoxic test for a 
variety of chemical compounds. The effect of extracts on the growth 
of HepG2 cells was assessed by the MTT assay. The IC50 value was 
calculated as 10.45 μ 0.31 øg/mL for A. vera extract and 9.60 μ 
0.01 øg/mL for C. comosum extract (Figure 1).
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Figure 1. A: Evaluation of IC50 for different concentrations of C. comosum 
on HepG2 cells, IC50 = 9.60 μ0.01 øg/mL derived from at least n = 4 
replicates μ SEM. B. Evaluation of IC50 for different concentrations of A. 
vera on HepG2 cells, IC50 = 10.45 μ0.31 øg/mL derived from at least n = 4 
replicates μ SEM. 
3.2. Assay for apoptosis and DNA damage by direct staining 
methods
   Annexin V staining for detection of apoptosis and DNA damage 
using Annexin V-FITC apoptosis kit showed considerable increased 
DNA damage in HepG2 cells (2 ė105 cells/mL) exposed to the 
extracts for 48 h in compared with control cells (Figures 2-3). It 
was detected that a high percentage of apoptosis with increasing 
the dose of extracts and the percentage of dead cells were increased 
(Figure 2). We also have found a positive co-relation between 
dead cells stained with FITC annexin and propidum iodide of each 
concentration and IC50 of each extract which is highly significant 
(Table 2). Microscopically, sections stained with H & E showed 
marked reduction in number of HepG2 cells at 10.45 øg/mL for A. 
vera extract and 9.60 øg/mL for C. comosum extract (Figures 4-5). 
Moreover, it was noticed most of morphological changes associated 
with apoptosis like nuclear condensation, membrane blobbing, 
nuclear fragmentation and apoptotic bodies were observed in the 
treated cells by C. comosum extract specially. Interestingly, C. 
Figure 2. Quadrant statistic analysis of flow cytometer shows the percentages of apoptosis in which upper left means necrotic cells, lower left means viable 
cells, upper right means late apoptotic cells and lower right means early apoptotic cells.  a: control HepG2 cell line; b: HepG2 cell line treated with 2.50 øg/mL 
of A. vera; c: HepG2 cell line treated 7.50 øg/mL of A. vera;  d: HCC cell line treated with 10.45 øg/mL of A. vera; e: HepG2 cell line treated with 2.5 øg/mL 
of C. comosum; f: HepG2 cell line treated with 7.5 øg/mL of C. comosum; g: HepG2 cell line treated with 9.6 øg/mL of C. comosum.
These percentages were the mean of 3 replicates.
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comosum revealed dose dependant effect (Figure 4).
Figure 4. A: Control HepG2 cell line (HE × 200); B: HepG2 cell line 
treated with 10.45 øg/mL of A. vera (HE × 200); C: HepG2 cell line 
treated with 9.6 øg/mL of C. comosum shows the presence of marked 
morphological changes associated with apoptotic cells (HE × 200). 
VC: viable cells, NC: necrotic cells and AC: apoptotic cells.  
AC
AC
VC VC
VC
VC
VC
AC
AC
AC
AC
A B
C
NC
NC
NC
Table 2
There is a highly significant positive correlation between necrotic cells for 
each concentration and IC50.
IC50 correlations
R (Co-relation 
coefficient)
P value
IC50 and necrotic cells 0.548 0.01
IC50 and necrotic cells in A. vera 0.713 0.03
IC50 and necrotic cells in C. comosum 0.909 0.01
3.3. P53 and Bcl-2 gene expression in HepG2 cells
   P53 and Bcl-2 gene expression were normalized to the house 
keeping GAPDH gene. As evident from charts (Figure 6) real time 
PCR evaluation of HepG2 cells treated with different concentrations 
of the extracts showed in a significant dose and time dependent 
increase in p53 mRNA expression along with a significant decrease 
in Bcl-2 mRNA expression.
3.4. Analysis of p53 and Bcl-2 proteins expression
   As showed in Figures 7 and 8, flow cytometer analysis of p53 and 
Bcl-2 protein expression in HepG2 cells (2 × 105 cells/mL) treated 
Figure 3. Detection of DNA damage. Increase in DNA damage as evident for apoptosis with increasing the dose of extracts A: Control cells; B: A. vera 
2.50 øg; C: C. comosum 2.5 øg; D: A. vera 7.50 øg; E: C. comosum 7.5 øg; F: A. vera 10.45 øg; G: C. comosum 9.6 øg.
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Figure 6. Detection of P53 protein percentage by flow cytometry shows up regulation of P53 protein in a dose and time dependent manner. A: Control HepG2 cell 
line: (31.24 μ 0.80)%; B: HepG2 cell line treated with 2.50 øg/mL of A. vera: (36.45 μ 0.79)%; C: HepG2 cell line treated 7.50 øg/mL of A. vera: (62.17 μ 0.58)%; 
D: HCC cell line treated with 10.45 øg/mL of A. vera: (82.91 μ 0.76) %; E: HepG2 cell line treated with 2.5 øg/mL of C. comosum: (33.40μ1.07)%; F: HepG2 cell 
line treated with 7.5 øg/mL of C. comosum: (62.73 μ 1.96)%; G: HepG2 cell line treated with 9.6 øg/mL of C. comosum: (75.62 μ 1.04)%. 
Results were derived from at least n = 3 replicates μ SE.
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Figure 7. Detection of Bcl-2 protein by flow cytometry shows down regulation of Bcl-2 protein in a dose and time dependent manner. A: Control HepG2 cell 
line: (57.51 μ 3.45)%; B: HepG2 cell line treated with 2.50 øg/mL of A. vera: (57.61 μ 3.45)%; C: HepG2 cell line treated 7.50 øg/mL of A. vera: (47.96 μ 
0.85)%; D: HCC cell line treated with 10.45 øg/mL of A. vera: (21.71μ 0.95)%; E: HepG2 cell line treated with 2.5 øg/mL of C. comosum: (70.25 μ 0.59)%; 
F: HepG2 cell line treated with 7.5 øg/mL of C. comosum: (35.12 μ2.51)%; G: HepG2 cell line treated with 9.6 øg/mL of C. comosum: (26.43μ1.64)%. 
Results were derived from at least n = 3 replicates μ SE.
0 
   
 4
0 
   
 8
0 
   
12
0 
   
16
0 
 2
00
 
0 
   
 4
0 
   
 8
0 
   
12
0 
   
16
0 
 2
00
 
0 
   
 4
0 
   
 8
0 
   
12
0 
   
16
0 
 2
00
 
0 
   
 4
0 
   
 8
0 
   
12
0 
   
16
0 
 2
00
 
0 
   
 4
0 
   
 8
0 
   
12
0 
   
16
0 
 2
00
 
0 
   
 4
0 
   
 8
0 
   
12
0 
   
16
0 
 2
00
 
0 
   
 4
0 
   
 8
0 
   
12
0 
   
16
0 
 2
00
 
C
ou
nt
C
ou
nt
C
ou
nt
C
ou
nt
C
ou
nt
C
ou
nt
C
ou
nt
A
E F G
B C D
M1
M1
M1
M1 M1
M1 M1
100            101             102               103          104
100            101             102               103          104 100            101             102               103          104 100            101             102               103          104
100            101             102               103          104 100            101             102               103          104 100            101             102               103          104
FL1-H
FL1-H FL1-H FL1-H
FL1-H FL1-H FL1-H
BCL2 protein expression HepG2
Cells: 77.35%
BCL2 protein expression HepG2
Cells: 70.25%
BCL2 protein expression HepG2
Cells: 35.12%
BCL2 protein expression HepG2
Cells: 26.43%
BCL2 protein expression HepG2
Cells: 57.61%
BCL2 protein expression HepG2
Cells: 47.96%
BCL2 protein expression HepG2
Cells: 21.71%
A C DB
Figure 6. Real time-PCR analysis of Bcl-2 gene in control and tested cells with A. vera (A) and C. comosum (B) shows down regulation of Bcl-2 gene expression; 
Real time-PCR analysis of p53 gene in control and tested cells with  A. vera (C) and C. comosum (D) shows up regulation of p53 gene expression.  
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with different concentrations of the standardized extracts for 48 
h also resulted in a time and dose dependent up regulation of p53 
along with a down regulation of Bcl-2 when compared to control 
samples which confirmed the results from q-PCR analysis of p53 and 
Bcl-2 mRNA expression in HepG2 cells. 
4. Discussion
   Recently, many of publications showed the effect of many 
herbal plants in treatment of wide range of illnesses. Also several 
naturally produced herbal formulations are currently available 
for cancer patients. As most of chemotherapeutic agents were 
cytotoxic to normal cells and developed drug resistance[14]. 
Therefore scientific consideration and test of traditionally used 
herbs for the treatment of different malignancies could be also 
considered as a very valuable source for new chemotherapeutic 
drugs[15]. A number of studies carried out over the last few decades 
on prevention and treatment of HCC have led to the identification 
of several herbal compounds and formulations that can affect 
the initiation, promotion as well as the progression processes 
of HCC[16]. The most important active constituents of the Aloe 
plants were anthraquinones like aloin, barbalion, anthranol, 
cinnamic acid, aloetic acid, emodin, chrysophanic acid, resistanol, 
and enzymes (including cyclooxygenase and bradykininase), 
together with Other compounds such as vitamins, saccharides, 
and amino acids[17]. It was reported that the other anthraquinones 
of Aloe plants had mutagenic and genotoxic effects in bacterial 
and mammalian test systems[18-19], the genotoxic effects were 
illustrated in present research by DNA damage assay and Real 
Time-PCR. The antitumor activity of 50% ethanol extract (100 mg/
kg) of A. vera was evaluated by Bharath[20]against Ehrlich ascites 
carcinoma tumor in mice. Ethanol extract of A. vera exhibited 
antitumor effect by modulating lipid peroxidation and augmenting 
antioxidant defense system in Ehrlich ascites carcinoma bearing 
mice[20]. Also, Aloe-emodin is one of the active components in 
the leaves of A. vera[21] which revealed anticancer and cytotoxic 
activities against neuroectodermal tumors, lung squamous cell 
carcinoma and hepatoma cells[22-24]. C. comosum also, has been 
exhibited anti- inflammatory, anti-ulcer and anti-cancer activities 
in rat and shrimp animals model[25], Dehydrodicatechin A is an 
active component of C. comosum which inhibits the growth of 
Ehrlich ascites[26]. Abdel-Sattar et al.[27] showed that C. comosum 
methanolic and aqueous extracts ameliorated haloperidol induced 
neuro- and hepatotoxicities in male Albino rat. In our study, we 
have noticed that the cytotoxic activity of A. vera and C. comosum 
might be through modulation of apoptosis, therefor both extracts 
demonstrated antitumor effects against HepG2 cells. Gene and 
protein expressions of both p53 and Bcl2 were significantly altered 
in response to extracts. Up-regulation of expression of p53 and 
down-regulation of Bcl2 in a time and dose dependent manner 
were evident in the human HCC cell line which is a major pathway 
for regulation of programmed cell death. Both extracts could have 
cytotoxic and genotoxic activity. C. comosum showed a higher 
level in inducing morphological changes associated apoptosis, DNA 
damage, gene and protein expressions. 
   In conclusion, the present study demonstrated that the herbal 
extracts of A. vera and C. comosum could induce cytotoxic and 
genotoxic activites on human hepatocellular carcinoma (HepG2) 
cells through induction of apoptotic pathway.   
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Comments 
Background
   HCC is among the most lethal and common malignancies in the 
human population, with approximately 550 000 new cases and 
almost as many deaths per year. For instance, a highly rate of HCC 
is observed in Egypt, where there is a high prevalence of hepatitis B 
and C viral infections.
  
Research frontiers
   The present research work depicts to evaluate the anti-tumor 
effect of different doses of A. vera and C. comosum extracts on HCC 
through assessment in vitro cytotoxicity induced apoptosis in HepG2 
cell line.
Related reports
   The most important active constituents of the Aloe plants were 
anthraquinones like aloin, barbalion, anthranol, cinnamic acid, 
aloetic acid, emodin, chrysophanic acid, resistanol, and enzymes 
(including cyclooxygenase and bradykininase), together with other 
compounds such as vitamins, saccharides, and amino acids.
Innovations and breakthroughs
   The present study demonstrated that the herbal extracts of A. vera 
and C. comosum could induce cytotoxic and genotoxic activites on 
human hepatocellular carcinoma (HepG2) cells through induction of 
apoptotic pathway. 
Applications
   Recently, many of publications showed the effect of many herbal 
plants in treatment of wide range of illnesses. Also several naturally 
produced herbal formulations are currently available for cancer 
patients.   
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Peer review
   Up-regulation of expression of p53 and down-regulation of 
Bcl2 in a time and dose dependent manner were evident in the 
human HCC cell line which is a major pathway for regulation 
of programmed cell death. Both extracts could have cytotoxic 
and genotoxic activity. C. comosum showed a higher level in 
inducing morphological changes associated apoptosis, DNA 
damage, gene and protein expressions. In conclusion, the present 
study demonstrated that the herbal extracts of A. vera and C. 
comosum could induce cytotoxic and genotoxic activites on human 
hepatocellular carcinoma (HepG2) cells through induction of 
apoptotic pathway. 
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